<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391959</url>
  </required_header>
  <id_info>
    <org_study_id>AZ202001</org_study_id>
    <nct_id>NCT04391959</nct_id>
  </id_info>
  <brief_title>Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)</brief_title>
  <official_title>A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azura Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azura Ophthalmics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients
      with Meibomian Gland Dysfunction (MGD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZ202001 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group
      study evaluating the safety, efficacy and tolerability of AZR-MD-001 ointment and AZR-MD-001
      vehicle in patients with Meibomian Gland Dysfunction (MGD)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meibum Gland Secretion Score (MGS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from Baseline in MGS. The MGS can range from 0 (highly abnormal) to 45 (Normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Meibomian Glands Yielding Liquid Secretion (MGYLS)</measure>
    <time_frame>Day 14 to Month 3</time_frame>
    <description>Change from Baseline in MGYLS. The MGYLS can range from 0 (abnormal) to 15 (normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total OSDI</measure>
    <time_frame>Day 14 to Month 3</time_frame>
    <description>Change from Baseline in Total Ocular Surface Disease Index (OSDI). The Total OSDI can range from 0 (normal) to 100 (abnormal)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 Vehicle will be dosed up to twice weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 Active will be dosed up to twice weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Active</intervention_name>
    <description>AZR-MD-001 is an active ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Active</arm_group_label>
    <other_name>AZR-MD-001 is an ophthalmic ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Vehicle</intervention_name>
    <description>AZR-MD-001 is a vehicle ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
    <other_name>AZR-MD-001 Vehicle is an ophthalmic ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18 years of age or older

          -  Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent), using the
             logarithm of the minimum angle of resolution (LogMAR) in each eye

          -  Evidence of meibomian gland obstruction

          -  Reported dry eye signs and symptoms within the past 3 months

        Exclusion Criteria:

          -  Uncontrolled ocular disease (except for MGD and dry eye disease/keratoconjunctivitis
             sicca) or uncontrolled systemic disease

          -  Glaucoma, ocular hypertension, or intraocular pressure (IOP) in either eye at
             screening â‰¥24 mm Hg or has planned insertion/removal of glaucoma filtration
             shunts/devices during the study

          -  Corneal abnormality or disorder that impacts normal spreading of the tear film or
             corneal integrity

          -  BCVA worse than 20/40 in either eye

          -  Current use of punctal plugs, anticipated insertion during the study, or a history of
             punctal cautery in either eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Tan-Showyin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Optometry and Vision Science, University of New South Wales</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Bosworth, PhD</last_name>
    <phone>7145598435</phone>
    <email>charles.bosworth@azuraophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Gleeson</last_name>
    <phone>+61 422 956 128</phone>
    <email>admin@azuraophthalmics.com</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

